Gainers
- Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
- Ensysce Biosciences, Inc. (NASDAQ: ENSC) climbed 73.1% to settle at $0.8684.
- Fast Radius, Inc. (NASDAQ: FSRD) gained 37.2% to close at $0.6296.
- Yoshitsu Co., Ltd (NASDAQ: TKLF) jumped 36.3% to close at $1.69.
- Rapid Micro Biosystems, Inc. (NASDAQ: RPID) jumped 35.2% to settle at $4.30 after Kennedy Lewis Investment Management LLC announced an offer to acquire Rapid Micro Biosystems.
- Aytu BioPharma, Inc. (NASDAQ: AYTU) gained 33.6% to close at $0.69. Aytu BioPharma appointed Vivian Liu to the company's board of directors, effective July 1, 2022.
- RiceBran Technologies (NYSE: RIBT) surged 29.6% to close at $0.67.
- Ipsidy Inc. (NASDAQ: AUID) gained 29.3% to close at $1.94.
- Volcon, Inc. (NASDAQ: VLCN) rose 26.9% to settle at $1.84.
- Tuniu Corporation (NASDAQ: TOUR) surged 26% to close at $1.05.
- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares gained 23.4% to close at $3.38 after the company announced results from a biomarker study to evaluate the potential of CogniC, a combination drug for Alzheimer's disease (AD).
- Immunome, Inc. (NASDAQ: IMNM) gained 22.1% to close at $3.21.
- Biodesix, Inc. (NASDAQ: BDSX) surged 21.5% to close at $1.64. Philips incorporated Biodesix blood-based proteomic nodule risk assessment testing into lung cancer orchestrator to advance early lung cancer diagnosis.
- Franklin Covey Co. (NYSE: FC) surged 21.4% to close at $46.18 after reporting Q3 results.
- Celularity Inc. (NASDAQ: CELU) gained 21% to settle at $3.40.
- Kewaunee Scientific Corporation (NASDAQ: KEQU) climbed 20.9% to close at $16.62.
- Pharming Group N.V. (NASDAQ: PHAR) gained 20.3% to close at $8.76.
- Dermata Therapeutics, Inc. (NASDAQ: DRMA) climbed 19.7% to close at $0.6501.
- Revlon, Inc. (NYSE: REV) climbed 18.1% to close at $5.42 on continued post-bankruptcy volatility. The stock has been mentioned on social media as a potential short squeeze candidate.
- Aspen Aerogels, Inc. (NYSE: ASPN) shares climbed 17.2% to close at $9.88 after the company announced its decision not to proceed with concurrent public offerings of common stock and green convertible senior notes due 2027.
- ADS-TEC Energy PLC (NASDAQ: ADSE) gained 17.1% to close at $6.64.
- Hippo Holdings Inc. (NYSE: HIPO) surged 15.9% to close at $0.8786.
- Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 15.2% to close at $1.13. Evofem Biosciences recently announced an agreement with a pharmacy benefit manager.
- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) gained 15% to close at $0.9927.
- EZFill Holdings Inc. (NASDAQ: EZFL) climbed 14.3% to close at $0.80.
- Silver Spike Investment Corp. (NASDAQ: SSIC) gained 14.3% to close at $9.78.
- IperionX Limited (NASDAQ: IPX) jumped 13.1% to close at $5.80.
- Remark Holdings, Inc. (NASDAQ: MARK) jumped 11.3% to close at $0.4410.
- Northern Lights Acquisition Corp. (NASDAQ: NLIT) gained 11.3% to settle at $10.61.
- AEye, Inc. (NASDAQ: LIDR) gained 8.5% to close at $1.91.
- HeartCore Enterprises, Inc. (NASDAQ: HTCR) rose 8.2% to close at $2.37.
- Applied Therapeutics, Inc. (NASDAQ: APLT) rose 7.8% to close at $0.9482. Applied Therapeutics recently announced a $30 million public offering of common stock and warrants.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers
- Cryptyde Inc. (NASDAQ: TYDE) shares dipped 67.8% to close at $2.03 on Thursday.
- Akerna Corp. (NASDAQ: KERN) declined 53% to close at $0.1382 after the company announced pricing of a $10 million public offering.
- Renalytix Plc (NASDAQ: RNLX) fell 38.3% to close at $2.45.
- First Wave BioPharma, Inc. (NASDAQ: FWBI) shares fell 37.5% to close at $0.20.
- Talaris Therapeutics, Inc. (NASDAQ: TALS) fell 36.8% to close at $4.51. Talaris Therapeutics issued FREEDOM-1 Phase 3 clinical update.
- Angion Biomedica Corp. (NASDAQ: ANGN) fell 33.3% to close at $1.14. Angion Biomedica discontinued the JUNIPER Phase 2 trial of ANG-3070, an oral tyrosine kinase inhibitor, in primary proteinuric kidney diseases, specifically focal segmental glomerulosclerosis and immunoglobulin A nephropathy.
- COMSovereign Holding Corp. (NASDAQ: COMS) shares fell 32% to close at $0.1690 after jumping over 60% on Wednesday.
- Kalera Public Limited Company (NASDAQ: KAL) declined 31.9% to close at $5.90.
- Aditxt, Inc. (NASDAQ: ADTX) fell 28.5% to close at $0.1431.
- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) fell 27% to close at $1.08.
- Brickell Biotech, Inc. (NASDAQ: BBI) fell 26.7% to close at $0.1260 after jumping around 48% on Wednesday.
- PetVivo Holdings, Inc. (NASDAQ: PETV) dropped 26.5% to close at $1.58. PetVivo posted FY22 loss of $0.57 per share.
- Enjoy Technology, Inc. (NASDAQ: ENJY) dipped 25.2% to close at $0.2169.
- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) fell 25.1% to close at $0.1910. Allena Pharmaceuticals shares jumped 114% on Wednesday after the company announced it has terminated its previously announced at-the-market offering.
- Agile Therapeutics, Inc. (NASDAQ: AGRX) fell 24.4% to settle at $1.1650 after the company filed for an offering of up to approximately 15.75 million shares
- Grove Collaborative Holdings, Inc. (NYSE: GROV) fell 24.2% to close at $4.63.
- Aeterna Zentaris Inc. (NASDAQ: AEZS) fell 23.8% to close at $0.1968.
- Lytus Technologies Holdings PTV. Ltd. (NASDAQ: LYT) fell 23.7% to settle at $4.16.
- Exicure, Inc. (NASDAQ: XCUR) fell 22.1% to close at $2.16 following effect of 1:30 reverse stock split.
- 9 Meters Biopharma, Inc. (NASDAQ: NMTR) declined 21.5% to close at $0.2608. 9 Meters Biopharma disclosed preliminary results from Phase 2 study of vurolenatide in short bowel syndrome.
- The9 Limited (NASDAQ: NCTY) fell 21.1% to close at $1.68.
- Codiak BioSciences, Inc. (NASDAQ: CDAK) fell 20.9% to close at $2.88. Codiak BioSciences announced platform-validating clinical data from Phase 1 trials of exoSTING and exoIL-12, and it plans to advance both candidates into Phase 2 trials.
- Duck Creek Technologies, Inc. (NASDAQ: DCT) fell 19.3% to close at $14.85 after the company issued Q4 and FY22 sales guidance below estimates. The company also reported a year-over-year decrease in Q3 EPS results.
- SMART Global Holdings, Inc. (NASDAQ: SGH) shares fell 19.3% to close at $16.37. SMART Global reported upbeat results for its third quarter, but issued weak forecast for the current quarter. The company also agreed to acquire Stratus Technologies for $225 million in cash at closing and an earn-out payment of up to $50 million.
- Biophytis S.A. (NASDAQ: BPTS) fell 19.3% to close at $1.13.
- Canopy Growth Corporation (NASDAQ: CGC) dropped 18.6% to close at $2.85 after the company announced it entered into exchange agreements with holders of approximately $198 million of convertible notes. Also, Piper Sandler lowered its price target on the stock from $4 to $3.
- Enochian Biosciences, Inc. (NASDAQ: ENOB) fell 18.6% to close at $1.93
- Icosavax, Inc. (NASDAQ: ICVX) dropped 18.2% to close at $5.73. Icosavax recently announced interim results from its Phase 1/1b clinical trial of its IVX-121 RSV F antigen in young and older adults.
- Amarin Corporation plc (NASDAQ: AMRN) declined 18.1% to settle at $1.49. Amarin announced REDUCE-IT exploratory post hoc biomarker sub-analysis showed relatively small changes in inflammatory markers between icosapent ethyl and placebo.
- Advanced Human Imaging Limited (NASDAQ: AHI) fell 18.1% to close at $0.58.
- Hyperfine, Inc. (NASDAQ: HYPR) shares fell 17.4% to close at $2.23. Hyperfine appointed Scott Huennekens as Interim President & CEO.
- Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) declined 17% to close at $1.86. Lexicon Pharmaceuticals reported positive topline results from the Phase 2 proof-of-concept study of its lead candidate LX9211 in painful diabetic neuropathy.
- Mereo BioPharma Group plc (NASDAQ: MREO) fell 17% to close at $1.12.
- Avenue Therapeutics, Inc. (NASDAQ: ATXI) declined 16.8% to close at $0.2693.
- Aethlon Medical, Inc. (NASDAQ: AEMD) fell 15.8% to close at $1.12.
- Borr Drilling Limited (NYSE: BORR) dropped 15.1% to close at $4.61.
- Culp, Inc. (NYSE: CULP) declined 14.5% to close at $4.30 following Q4 results.
- Aileron Therapeutics, Inc. (NASDAQ: ALRN) dipped 13.4% to close at $0.26. Aileron Therapeutics recently announced interim data from its Phase 1b NSCLC trial of ALRN-6924 and said it plans to stop further enrollment in the NSCLC trial.
- Femasys Inc. (NASDAQ: FEMY) fell 12.7% to close at $2.41 after gaining around 7% on Wednesday.
- Connect Biopharma Holdings Limited (NASDAQ: CNTB) shares fell 12.2% to close at $0.87 after gaining around 9% on Wednesday.
- Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) dropped 11.5% to close at $1.92 as the company reported pricing of public offering of common stock.
- NextPlay Technologies, Inc. (NASDAQ: NXTP) dropped 11.1% to close at $0.3494. NextPlay's In-Game Advertising unit, Hotplay entered into memorandum of understanding with Triplecom Media PVT.
- Endo International plc (NASDAQ: ENDP) fell 10.9% to close at $0.4657.
- Can-Fite BioPharma Ltd. (NYSE: CANF) fell 9.8% to settle at $0.92. Can-Fite BioPharma shares jumped over 15% on Wednesday after the company announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis.
- The Simply Good Foods Company (NASDAQ: SMPL) dropped 8.3% to close at $37.77 following Q3 results.
- Cooper-Standard Holdings Inc. (NYSE: CPS) fell 7.8% to close at $4.99.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Read at Benzinga